PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
Manuscript NO: 67003
Title: New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HE
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 04144629
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Assistant Professor
Reviewer’s Country/Territory: United States
Author’s Country/Territory: Spain
Manuscript submission date: 2021-04-19
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-05-07 19:51
Reviewer performed review: 2021-05-16 22:27
Review time: 9 Days and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The authors summarized the therapeutic advances which target genes uncommonly mutated in NSCLC. However, the info in this review appears not up-to-date. For sample, there are FDA approved therapies for NSCLC harboring BRAF V600E and Ret-fusions, and on 02.17.2021, The FDA granted priority review to sotorasib to treat patients with KRAS G12C–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). All these information was not covered in the review. Also BRAF Non-V600 mutations were not covered in the review.